SC Strata Critical Medical, Inc. Stock: price and insider trades · United States · SEC (Form 4)Track the Strata Critical Medical, Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Strata Critical Medical, Inc. has recorded 62 insider filings. Market capitalisation: €525.5m. The latest transaction was disclosed on 13 August 2026 (Cession). Among the most active insiders: Cohen Amir. The full history is openly available.
€435,921
7 ops.
Sell Volume
Analyst consensus: bullish or bearish? Analysts rate Strata Critical Medical, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$9.56.
Buys €84,068 €435,921 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 17,304 of 29,056 companies
FCF yld -11%
Earn yld 7.8%
EV/EBITDA ·
ROE -9.2%
Gross mgn 21%
Net mgn 21%
Debt/EBITDA ·
Pillars 2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 13 August 2026
All Executives62 Thresholds0 Prospectus0 Other0
Declarations 62 total
▼ Director · Executives · 10 Aug 2026
5,091 shares @ US$5.75 Class A common stock, $0.0001 par value per share SEC:0001628280-26-056841:0
◆ Chief Accounting Officer · Executives · 30 Jul 2026
41,786 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-051809:0
◆ Chief Accounting Officer · Executives · 30 Jul 2026
27,420 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-051809:1
◆ Director · Executives · 30 Jul 2026
44,438 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-051826:0
◆ Co-CEO and CFO · Executives · 30 Jul 2026
181,071 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-051814:0
◆ Director · Executives · 30 Jul 2026
30,913 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-051822:0
◆ Co-CEO and General Counsel · Executives · 30 Jul 2026
208,929 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-051811:0
◆ Co-CEO and General Counsel · Executives · 30 Jul 2026
206,953 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-051811:1
◆ Director · Executives · 30 Jul 2026
50,234 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-051819:0
● Chief Accounting Officer · Executives · 31 Jul 2026
34,015 shares @ US$5.09 0.040% mcap 21.2% of flow Class A common stock, $0.0001 par value per share SEC:0001628280-26-051809:2
◆ Co-CEO and CFO · Executives · 30 Jul 2026
179,160 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-051814:1
● Co-CEO and CFO · Executives · 31 Jul 2026
199,209 shares @ US$5.09 0.23% mcap 34.0% of flow Class A common stock, $0.0001 par value per share SEC:0001628280-26-051814:2
◆ Director · Executives · 30 Jul 2026
35,260 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-051817:0
◆ Director · Executives · 30 Jul 2026
37,675 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-051824:0
● Co-CEO and General Counsel · Executives · 31 Jul 2026
212,309 shares @ US$5.09 0.25% mcap 34.5% of flow Class A common stock, $0.0001 par value per share SEC:0001628280-26-051811:2
◆ CEO, Logistics · Executives · 30 Jul 2026
57,172 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-051816:0
● CEO, Logistics · Executives · 31 Jul 2026
13,992 shares @ US$5.09 0.016% mcap 27.6% of flow Class A common stock, $0.0001 par value per share SEC:0001628280-26-051816:1
▼ Chief Accounting Officer · Executives · 8 Jun 2026
4,655 shares Class A common stock, $0.0001 par value per share SEC:0001628280-26-042182:0
▼ Chief Accounting Officer · Executives · 21 May 2026
10,300 shares @ US$5.79 0.0094% mcap 11.7% of flow Class A common stock, $0.0001 par value per share SEC:0001628280-26-038171:0
▼ Chief Accounting Officer · Executives · 22 May 2026
40,575 shares @ US$5.91 0.038% mcap 47.0% of flow Class A common stock, $0.0001 par value per share SEC:0001628280-26-038171:1
▼ Chief Accounting Officer · Executives · 11 May 2026
14,306 shares @ US$5.79 0.017% mcap 38.7% of flow Class A common stock, $0.0001 par value per share SEC:0001628280-26-034586:0
◆ Chief Accounting Officer · Executives · 23 Apr 2026
83,505 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-027658:0
◆ Co-CEO and CFO · Executives · 23 Apr 2026
545,625 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-027654:0
◆ Co-CEO and General Counsel · Executives · 23 Apr 2026
630,264 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-027656:0
◆ CEO, Logistics · Executives · 23 Apr 2026
57,172 shares 0Class A common stock, $0.0001 par value per share SEC:0001628280-26-027661:0
25 of 62 declarations
Load more (37 remaining) 关于 Strata Critical Medical, Inc. Strata Critical Medical, Inc. (NASDAQ: SRTA) 是一家总部位于纽约的美国公司,专注于美国医疗保健市场的时间敏感物流和医疗服务。该公司前身为 Blade Air Mobility, Inc.,在 2025 年剥离其传统客运业务后,进行了重大的战略调整。此次交易后,Strata 成为一个更专注、合同驱动的“纯粹”医疗物流和临床服务平台,其商业模式受消费者旅行需求的影响较小,更扎根于医疗保健基础设施。
Strata 的核心产品围绕移植医院和器官获取组织的综合解决方案构建。该公司提供端到端的“一站式”解决方案,可包括航空和地面物流、器官分配、外科器官获取、常温区域灌注、保存服务以及相关的协调支持。这些能力主要通过 Trinity Medical Solutions 和 Keystone Perfusion Services 品牌提供。此外,Strata 还为心血管外科中心提供灌注人员配备和设备解决方案,将其可寻址市场扩展到移植相关手术之外。
从竞争角度来看,Strata 在一个专业利基市场运营,但该市场具有有利的结构性动态。需求受到持续的器官短缺、移植物流的操作复杂性以及减少整个护理路径中时间敏感延迟的需求的支持。该公司的主要差异化因素是其综合服务模式,该模式将运输、临床协调和程序执行整合到一个平台中。管理层将 Strata 描述为运营着美国移植医院和器官获取组织最大的航空运输和外科服务网络之一,这表明其在高度专业化的领域中具有重要的网络地位。
从地理上看,该业务主要在国内,以美国为中心,Strata 的主要行政办公室也设在纽约。该公司并未定位为广泛的国际运营商;相反,其战略似乎专注于深化其在美国的足迹,并在邻近的医疗关键工作流程中进行扩展。
最近的公司里程碑对股权投资者而言非常重要。2025 年 8 月,Strata 完成了将其客运业务出售给 Joby Aviation 的交易,正式完成了战略转型,并开始在纳斯达克以新股票代码 SRTA 交易。2025 年 9 月,该公司完成了对 Keystone Perfusion Services 的收购,加强了其在器官获取、常温区域灌注和灌注相关医疗服务方面的能力。最近,该公司在 2026 年的披露中报告了 2025 年强劲的运营势头,包括收入增长和改善的指导,这表明其业务概况更加精简,并且围绕关键医疗服务的盈利叙述更加清晰。